Special Feature: Interview with the “Business Strategy Division”
The Business Strategy Division’s Vision for JPMA’s New Direction:
In April 2026, the JPMA launched a new organization, the “Business Strategy Headquarters,” to support the Chairman and Vice Chairmen. With its transition to a general incorporated association scheduled for October, where is the JPMA headed? We take a closer look at the JPMA’s new direction as it takes on the challenge of establishing a cross-functional command center.
From JPMA
Interview with the New Chairperson:
—Pioneering the Future of the Pharmaceutical Industry Through Co-Creation
New Chairpersons took office in each committee starting in fiscal year 2026. In this special feature, we asked the six new Chairpersons about the challenges facing their respective committees, their future goals, their aspirations as Chairpersons, and their messages to other committees regarding collaborative innovation.
My Committee
Vol. 7: Regulatory Affairs Committee
The Regulatory Affairs Committee, centered on the “Drug Application Subcommittee” and the “Regulatory System Subcommittee,” is working to expedite approval reviews and improve the regulatory system to ensure international harmonization. We present the members’ individual perspectives on topics such as the review of review report formats and institutional reforms regarding approval notices and change procedures.
The Pharmaceutical Industry from a Factual Perspective
: To What Extent Have Unmet Medical Needs Been Addressed?
The Office of Pharmaceutical Industry Research Based on the “Medical Needs Survey” targeting physicians, we have long tracked the progress of new drugs addressing unmet medical needs (UMN). Drawing on five key facts, we analyze the current state of drug discovery innovation and the challenges that remain.
Key words to keep in mind
Roadmap for Public-Private Investment in “Drug Discovery and Advanced Medical Care” under Japan’s Growth Strategy
Under the “Japan Growth Strategy,” “Drug Discovery and Advanced Medical Care” has been designated as one of 17 priority areas, and a “Public-Private Investment Roadmap” has been formulated.We spoke with Mr. Katsuaki Ura, Policy Planning and Research Officer at the Secretariat for Health and Medical Strategy Promotion, Cabinet Office, about the overall picture of this policy aimed at realizing a nation driven by drug discovery and the expectations for the pharmaceutical industry.
Topics
New member company Alnylam Japan K. K.; meetings between top global biopharmaceutical leaders and Prime Minister Sanae Takaichi; participation in “Yakusai 2026”; polypharmacy awareness campaigns; “Practical Interviews on Participation and Collaboration” for patient groups;we bring you the latest initiatives and achievements of the JPMA, including patients’ online pharmaceutical information search behavior as seen through positioning map analysis and information provision strategies for the AI era.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire